BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Phase 2
Completed
- Conditions
- PostmenopausePre-HypertensionHypertension
- Interventions
- Drug: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)Drug: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 92
- Registration Number
- NCT00420342
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT00414687
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1493
- Registration Number
- NCT00410306
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Phase 3
Completed
- Conditions
- AbscessWound InfectionUlcerDiabetic Foot
- Interventions
- Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 813
- Registration Number
- NCT00402727
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 613
- Registration Number
- NCT00402467
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 726
- Registration Number
- NCT00398905
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 877
- Registration Number
- NCT00396786
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
Phase 3
Completed
- Conditions
- Central Nervous System Diseases
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 147
- Registration Number
- NCT00395460
- Locations
- 🇨🇳
Fudan University Huashan Hospital, Shanghai, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳The 1st Affiliated Hosp of the 4th Military Med Uni, Xi'an, Shaanxi, China
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
Phase 3
Completed
- Conditions
- Vascular Diseases
- Interventions
- Drug: Gadopentate dimeglumine (Magnevist, BAY86-4882)
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00395733
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: (LMW) Heparin + Vitamin K Antagonist
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 543
- Registration Number
- NCT00395772
© Copyright 2025. All Rights Reserved by MedPath